CDC-RFA-CE23-2301: Domestic Violence Prevention Enhancement and Leadership Through Alliances (DELTA): Achieving Health Equity through Addressing Disparities (AHEAD)
Closed
This grant is closed. A newer notice from the same program is open now: NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) (PA-27-100). Status: Due dates in the notice, expires April 5, 2027. It is in our archive of Centers for Disease Control - NCIPC notices from 2022.
Centers for Disease Control - NCIPC offered grants of up to $500,000 (at least $250,000) to the applicants described in the notice. It expected to make about 22 awards worth $45.0 million in total. Applications closed on November 29, 2022.
From the official notice on Grants.gov, last changed November 14, 2022. Checked November 7, 2026.
- Award ceiling$500,000
- Award floor$250,000
- Total funding$45.0 million
- Expected awards22
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | September 22, 2022 |
|---|---|
| Deadline | November 29, 2022 |
| Archived by Grants.gov | December 29, 2022 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
As provided for in 42 USC § 10414, to be eligible for funding, an organization must: (1) be a State Domestic Violence Coalition; and (2) include representatives of pertinent sectors of the local community, which may include: (A) health care providers and State or local health departments; (B) the education community; (C) the faith-based community; (D) the criminal justice system; (E) family violence, domestic violence, and dating violence service program advocates; (F) human service entities such as State child services divisions; (G) business and civic leaders; (H) other pertinent sectors. For a list of HHS-designated State Domestic Violence Coalitions, see: https://www.acf.hhs.gov/fysb/state-dv-coalitions . If the applicant’s organization is not on this list, the applicant must provide a paragraph describing how they meet the above criteria. The term ‘State’ means each of the several States, the District of Columbia, the Commonwealth of Puerto Rico, and, except as otherwise provided, Guam, American Samoa, the United States Virgin Islands, and the Commonwealth of the Northern Mariana Islands. A Bona Fide Agent is an agency/organization identified by the state as eligible to submit an application under the state eligibility in lieu of a state application. If applying as a bona fide agent of a state or local government, a legal, binding agreement from the state or local government as documentation of the status is required. Attach with “Other Attachment Forms” when submitting via www.grantsolutions.gov.
Is this a realistic fit?
- Past Injury Prevention and Control Research and State and Community Based Programs awards averaged $2.2 million; this notice allows up to $500,000 per award.
- Most of the program's money (76% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
The cooperative agreements with the SDVCs are established for the purposes of establishing, operating, and maintaining local community projects to prevent family violence, domestic violence, and dating violence, including violence committed by and against youth, using a Coordinated Community Response (CCR) model and through prevention and education programs.
Who has won Injury Prevention and Control Research and State and Community Based Programs grants before
From fiscal 2021 to 2025, Injury Prevention and Control Research and State and Community Based Programs (93.136) awarded $2.2 billion across 986 grant awards, an average of $2.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Florida Department of Health | Florida | 12 | $81.1 million |
| California Department of Public Health | California | 11 | $55.4 million |
| Ohio Department of Health | Ohio | 9 | $42.0 million |
| North Carolina Department of Health & Human Services | North Carolina | 12 | $42.0 million |
| Michigan Department of Health and Human Services | Michigan | 10 | $37.9 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PA-27-100, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-CE23-2301 still open?
No. It closed on November 29, 2022. A newer notice is open: PA-27-100, due dates in the notice, expires April 5, 2027.
Who can apply for Domestic Violence Prevention Enhancement and Leadership Through Alliances (DELTA): Achieving Health Equity through Addressing Disparities (AHEAD)?
Centers for Disease Control - NCIPC accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Domestic Violence Prevention Enhancement and Leadership Through Alliances (DELTA): Achieving Health Equity through Addressing Disparities (AHEAD)?
Closed November 29, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $500,000 each. About $45.0 million in total across about 22 awards.
Who has won Injury Prevention and Control Research and State and Community Based Programs grants before?
The largest recipients over five fiscal years were Florida Department of Health, California Department of Public Health, Ohio Department of Health. The program made 986 awards worth $2.2 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)